Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Researchers from University of Barcelona, Medical Department discuss findings in breast cancer
November 20th, 2008
According to recent research published in the journal Breast Cancer Research and Treatment, "Histone deacetylase inhibitors (HDACi) are a new class of anticancer agents that cause growth arrest, differentiation and/or apoptosis in many tumor cells. As acetylation regulates the activity of the anti-apoptotic transcription factor NF-kappa B, we investigated whether the proteasome inhibitor MG-132 would inhibit NF-kappa B activation and as a consequence potentiate HDACi-dependent apoptosis in breast cancer cells." "We observed that the HDACi suberoylanilide hydroxamic acid (SAHA) or trichostatin A (TSA) induced cell death but also enhanced NF-kappa B-activity. This...
Source: Women's Health Weekly (2008-11-20)
|
